Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Phase 3

Completed

Conditions: Anemia
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-04-25

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 275

Registration Number: NCT00003341

Locations: 🇺🇸
Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States
🇺🇸
Division of Oncology, Palo Alto, California, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 15 locations

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-04-25

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 80

Registration Number: NCT00003346

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Childhood Germ Cell Tumor
Retinoblastoma
Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Ovarian Cancer

First Posted Date: 2003-04-23

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT00003173

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: cisplatin
Drug: lomustine
Drug: vincristine sulfate
Procedure: adjuvant therapy
Radiation: iodine I 131 monoclonal antibody 3F8
Radiation: radiation therapy

First Posted Date: 2003-04-09

Last Posted Date: 2020-05-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT00058370

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2013-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00058435

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-04-09

Last Posted Date: 2013-05-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00058396

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: darbepoetin alfa
Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: indium In 111 ibritumomab tiuxetan
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-04-09

Last Posted Date: 2020-11-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 65

Registration Number: NCT00058422

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2011-04-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00055705

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002697

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00030849

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy